Cited by 635Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 197 of the 200 references it cites were found in a registry or an index, and 3 are not checked yet.

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Open access

Viola, Kirsten L., Klein, William L.·2015·Acta Neuropathologica

DOI 10.1007/s00401-015-1386-3PMC PMC4390393

Open this paper in CoChat — free account

Abstract

Protein aggregation is common to dozens of diseases including prionoses, diabetes, Parkinson's and Alzheimer's. Over the past 15 years, there has been a paradigm shift in understanding the structural basis for these proteinopathies. Precedent for this shift has come from investigation of soluble Aβ oligomers (AβOs), toxins now widely regarded as instigating neuron damage leading to Alzheimer's dementia. Toxic AβOs accumulate in AD brain and constitute long-lived alternatives to the disease-defining Aβ fibrils deposited in amyloid plaques. Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent. The AD-like cellular pathologies induced by AβOs suggest their impact provides a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Alternative ideas for triggering mechanisms are being actively investigated. Some research favors insertion of AβOs into membrane, while other evidence supports ligand-like accumulation at particular synapses. Over a dozen candidate toxin receptors have been proposed. AβO binding triggers a redistribution of critical synaptic proteins and induces hyperactivity in metabotropic and ionotropic glutamate receptors. This leads to Ca(2+) overload and instigates major facets of AD neuropathology, including tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Because different species of AβOs have been identified, a remaining question is which oligomer is the major pathogenic culprit. The possibility has been raised that more than one species plays a role. Despite some key unknowns, the clinical relevance of AβOs has been established, and new studies are beginning to point to co-morbidities such as diabetes and hypercholesterolemia as etiological factors. Because pathogenic AβOs appear early in the disease, they offer appealing targets for therapeutics and diagnostics. Promising therapeutic strategies include use of CNS insulin signaling enhancers to protect against the presence of toxins and elimination of the toxins through use of highly specific AβO antibodies. An AD-dependent accumulation of AβOs in CSF suggests their potential use as biomarkers and new AβO probes are opening the door to brain imaging. Overall, current evidence indicates that Aβ oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00401-015-1386-3

Cites

197 of 200 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
Retracted
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citation
Journal of Biological Chemistry
Kurkinensp, M., CondongT, M. R., Blumberg, B., Barlow, D. P., Quiñones, S., Sausg, J., & Pihlajaniemisyy, T. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc · Cited by 3,427
Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
High-Level Neuronal Expression of Aβ1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856

Flagged first, then by citations

Show all 198 references

Research works printed but not linked: 1

Nigh AB, Vahedi S, Davis EG, Weintraub S, Bigio EH, Klein WL, Geula C (2014) Intracellular Amyloid-beta in cholinergic neurons. Brain J Neurol: In Press

Sorted by citations

Items 401–500 of 635

Direct Delivery of ANA-TA9, a Peptide Capable of Aβ Hydrolysis, to the Brain by Intranasal Administration
Hatakawa, Y., Tanaka, A., Furubayashi, T., Nakamura, R., Konishi, M., Akizawa, T., & Sakane, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101673 · Cited by 11
Enalaprilat Inhibits Zinc-Dependent Oligomerization of Metal-Binding Domain of Amyloid-beta Isoforms and Protects Human Neuroblastoma Cells from Toxic Action of these Isoforms
Kozin, S. A., Polshakov, V. I., Mezentsev, Y. V., Ivanov, A. S., Zhokhov, S. S., Yurinskaya, M. M., Винокуров, М. Г., Makarov, A. А., & Mitkevich, V. A. (2018) · Molecular Biology · doi:10.1134/s0026893318040106 · Cited by 11
Relative expression of the p75 neurotrophin receptor, tyrosine receptor kinase A, and insulin receptor in SH-SY5Y neuroblastoma cells and hippocampi from Alzheimer's disease patients
Ito, S., Ménard, M., Atkinson, T. G., Brown, L., Whitfield, J., & Chakravarthy, B. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.09.015 · Cited by 10
The Mode of Action of an Anti-Oligomeric Amyloid β-Protein Antibody Affects its Protective Efficacy
Zhang, Y., Huai, Y., Zhang, X., Song, C., Cai, J., & Zhang, Y. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9955-6 · Cited by 11
The endocrine pancreas of old obesehyperglycemic mice.
Westman, S. (1968) · PubMed · Cited by 11
Exploring nanoparticular platform in delivery of repurposed drug for Alzheimer’s disease: current approaches and future perspectives
Chakraborty, S., Vishwas, S., Harish, V., Gupta, G., Paudel, K. R., Dhanasekaran, M., Goh, B. H., Zacconi, F. C. M., Pinto, T. D. J. A., Kumbhar, P., et al. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2414768 · Cited by 11
Evidence for a Strong Relationship between the Cytotoxicity and Intracellular Location of β-Amyloid
Haque, M. A., Hossain, M. S., Bilkis, T., Islam, M. R., & Park, I. (2022) · Life · doi:10.3390/life12040577 · Cited by 10
Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer’s Disease
Yamalı, C., & Dönmez, Ş. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666221201145141 · Cited by 10
Exercise Reverses Amyloid β-Peptide–Mediated Cognitive Deficits in Alzheimer’s Disease Mice Expressing Mutant Presenilin-2
Hwang, D.-J., Choi, D.-H., Kwon, K.-C., Kim, E., Kim, T., Koo, J., & Cho, J. (2021) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002834 · Cited by 10
Alteration of global protein SUMOylation in neurons and astrocytes in response to Alzheimer's disease-associated insults
Maruyama, T., Wada, H., Abe, Y., & Niikura, T. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.104 · Cited by 10
Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine
Yu, Y., & Xu, Q. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1197456 · Cited by 10
Real-time monitoring of the amyloid β1–42 monomer-to-oligomer channel transition using a lipid bilayer system
Numaguchi, Y., Tsukakoshi, K., Takeuchi, N., Suzuki, Y., Ikebukuro, K., & Kawano, R. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad437 · Cited by 9
Excitatory-inhibitory synaptic imbalance induced by acute intra-hippocampus injections of amyloid-β oligomers
Arriagada, J., Mercerón‐Martínez, D., Ardiles, Á. O., Muñoz, P., & Paula-Lima, A. C. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151133 · Cited by 9
Controllable signal molecule release from Au NP-gated MSNs for photocathodic detection of ultralow level AβO
Zhang, X., Zhang, J., Gao, Y., Yan, J., & Song, W. (2021) · Chemical Communications · doi:10.1039/d1cc05220a · Cited by 9
Synthesis and In Vitro and In Vivo Evaluation of 18F-Labeled Positron Emission Tomography Tracers for Imaging Aβ Plaques
Zheng, W., Huang, Y. P., Chen, H., Jiang, Z., Yu, Z., Yang, T., Zhang, L., Cheng, X., Liu, Y., Liu, Q., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00025 · Cited by 9
Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases
Hu, C., Yan, Y., Jin, Y., Yang, J. H., Xi, Y., & Zhong, Z. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01115-9 · Cited by 11
Impacts of glutamate, an exercise-responsive metabolite on insulin signaling
Xing, X., Sun, Q., Wang, R., Wang, R., & Wang, R. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122471 · Cited by 10
Mitophagy in Alzheimer’s Disease: A Bibliometric Analysis from 2007 to 2022
Wang, H., Yan, X., Zhang, Y., Wang, P., Li, J., & Zhang, X. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230139 · Cited by 9
Cleavage site-directed antibodies reveal the prion protein in humans is shed by ADAM10 at Y226 and associates with misfolded protein deposits in neurodegenerative diseases
Song, F., Kovač, V., Mohammadi, B., Littau, J. L., Scharfenberg, F., Matamoros‐Angles, A., Vanni, I., Shafiq, M., Orge, L., Galliciotti, G., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02763-5 · Cited by 9
Inhibition of tissue transglutaminase promotes Aβ-induced apoptosis in SH-SY5Y cells
Zhang, J., Ding, Y., & Wang, R. C. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.95 · Cited by 9
Oligomerization Alters Binding Affinity between Amyloid Beta and a Modulator of Peptide Aggregation
Hilt, S., Rojalin, T., Viitala, T., Koivuniemi, A., Bunker, A., Wachsmann‐Hogiu, S., Kálai, T., Hideg, K., Yliperttula, M. L., & Voss, J. C. (2017) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.7b06164 · Cited by 9
The precious content of the olive mill wastewater: the protective effect of the antioxidant fraction in cell cultures
Giacomazza, D., D’Andrea, D., Provenzano, A., Picone, P., Provenzano, F., Guarrasi, V., Raimondo, M., Biagio, P. L. S., Passantino, R., Mangione, M. R., et al. (2018) · CyTA - Journal of Food · doi:10.1080/19476337.2018.1458752 · Cited by 9
Active immunization with norovirus P particle-based amyloid-β chimeric protein vaccine induces high titers of anti-Aβ antibodies in mice
Yang, P. C., Guo, Y., Sun, Y., Yu, B., Zhang, H., Wu, J., Yu, X., Wu, H., & Kong, W. (2019) · BMC Immunology · doi:10.1186/s12865-019-0289-9 · Cited by 9
Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid‐β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice
Yu, X., Zhu, J., Liu, X., Xu, P., Zhang, Y., & Liu, R. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15015 · Cited by 9
Benzo[d]imidazole-pyrrolo[1,2-a]pyrazine Hybrids Ameliorate Amyloid Aggregates in the Brain of Alzheimer Transgenic Mice
Cha, M., Dagar, A., Lee, S. H., Cho, I., Lee, D.-H., Kim, K., Park, I., Yoon, S., Kim, H. Y., Kim, I., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00547 · Cited by 9
Nanomaterials in targeting amyloid-β oligomers: current advances and future directions for Alzheimer's disease diagnosis and therapy
Randhawa, S., Saini, T. C., Bathla, M., Bhardwaj, R., Dhiman, R., & Acharya, A. (2025) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.16.44 · Cited by 8
Development of Neuroprotective Agents for the Treatment of Alzheimer's Disease using Conjugates of Serotonin with Sesquiterpene Lactones
Евгеньевна, Н. М., Liu, J., Aleksandrova, Y. R., Vasilieva, N., Семаков, А. В., Yandulova, E. Y., Sukocheva, O. A., Balakin, K. V., Klochkov, S. G., & Fan, R. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221125105253 · Cited by 8
Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer’s Disease
Zagorski, K., King, O., Hovakimyan, A., Petrushina, I., Antonyan, T., Chailyan, G., Ghazaryan, M., Hyrc, K. L., Chadarevian, J. P., Davtyan, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129797 · Cited by 8
An electrochemical aptasensor based on stimulus response and signal amplification strategy for the detection of Amyloid-β oligomers
Ren, Z., Guo, W., Umar, A., Zhao, C., Wang, L., Ibrahim, A. A., Alkhanjaf, A. A. M., Baskoutas, S., Pei, M., & Zhang, X. (2023) · Microchemical Journal · doi:10.1016/j.microc.2023.109377 · Cited by 8
A nonlinear meccano for Alzheimer's emergence by amyloid β-mediated glutamatergic hyperactivity
Bonifazi, G., Luchena, C., Gaminde‐Blasco, A., Ortiz-Sanz, C., Capetillo‐Zarate, E., Matute, C., Alberdi, E. M., & Pittà, M. D. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106473 · Cited by 9
Therapeutic Potential of Polyphenols in Cellular Reversal of Patho‐Mechanisms of Alzheimer's Disease Using In Vitro and In Vivo Models: A Comprehensive Review
Samal, M., Srivastava, V., Khan, M., Insaf, A., Penumallu, N. R., Alam, A., Parveen, B., Ansari, S. H., & Ahmad, S. (2024) · Phytotherapy Research · doi:10.1002/ptr.8344 · Cited by 8
Detecting and Tracking β-Amyloid Oligomeric Forms and Dynamics In Vitro by a High-Sensitivity Fluorescent-Based Assay
Zhao, Y., Brener, O., Andrzejewska, E., Wei, J., Reiß, C., Tietz, O., Knowles, T. P. J., & Aigbirhio, F. I. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00312 · Cited by 8
Amyloid-β oligomers drive amyloid deposit and cascaded tau pathology of Alzheimer's disease in aged brains of non-human primates
He, Z., Zhang, W., Chen, P., Li, S., Tao, M., Yue, F., Hong, W., Feng, S., & Jing, N. (2025) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2025.02.007 · Cited by 9
Amyloid‐β Dysregulates Oligodendroglial Lineage Cell Dynamics and Myelination via PKC in the Zebrafish Spinal Cord
Balantzategi, U., Gaminde‐Blasco, A., Kearns, C. A., Bayón‐Cordero, L., Sánchez‐Gómez, M. V., Zugaza, J. L., Appel, B., & Alberdi, E. M. (2025) · Glia · doi:10.1002/glia.70015 · Cited by 9
Alzheimer’s Disease Treated with Autologous and Allogeneic TelomerasePositive Stem Cells
Young, W., & Speight, M. O. (2021) · Stem Cell & Regenerative Medicine · doi:10.33425/2639-9512.1058 · Cited by 8
Aβ 42 oligomers can seed the fibrillization of Aβ 40 peptides
Wu, Y., Huang, S., Wu, M., Tu, L., Lee, M., & Chan, J. C. C. (2022) · Journal of the Chinese Chemical Society · doi:10.1002/jccs.202200136 · Cited by 7
Synthetic strategies of functionalized pyridines and their therapeutic potential as multifunctional anti-Alzheimer's agents
Shaik, J. B., Pinjari, M. K. M., Gangaiah, D. A., & Nallagondu, C. G. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91221-1.00014-2 · Cited by 8
Bias-generating factors in biofluid amyloid-β measurements for Alzheimer’s disease diagnosis
Park, S., & Kim, Y. S. (2021) · Biomedical Engineering Letters · doi:10.1007/s13534-021-00201-z · Cited by 8
Opposite in vivo effects of agents that stimulate or inhibit the glutamate/cysteine exchanger system on the inhibition of hippocampal LTP by Aß
Zhang, D., Jin, B., Ondrejčák, T., & Rowan, M. J. (2016) · Hippocampus · doi:10.1002/hipo.22667 · Cited by 8
BACE1 and SCD1 are associated with neurodegeneration
Bedoya-Guzmán, F. A., Pacheco‐Herrero, M., Salomon-Cruz, I. D., Barrera-Sandoval, Á. M., Vargas, J. A. G., Villamil-Ortiz, J. G., Villegas‐Lanau, C. A., Arias-Londoño, J. D., Área-Gómez, E., & Cardona‐Gómez, G. P. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1194203 · Cited by 7
Oral diseases as emerging risk factors for Alzheimer’s disease: A scoping review
Yi, Y., Lee, C., Shin, H., & Shin, S. (2025) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2025.11.003 · Cited by 8
Liquid–liquid phase separation in neurodegenerative diseases
Haider, R., Boyko, S., & Surewicz, W. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823967-4.00018-x · Cited by 7
Notoginsenoside R1 ameliorates the inflammation induced by amyloid‑β by suppressing SphK1‑mediated NF‑κB activation in PC12 cells
Wang, X., Li, B., Yu, X., Zhou, Y., Wang, K., & Gao, Y. (2023) · Molecular Medicine Reports · doi:10.3892/mmr.2023.13139 · Cited by 7
Delineation of the role of G6PD in Alzheimer’s disease and potential enhancement through microfluidic and nanoparticle approaches
Sharallah, O. A., Poddar, N. K., & Alwadan, O. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102394 · Cited by 7
Tyrosine modifications of insulin-degrading enzyme enable favorable control of substrate specificity for both Alzheimer’s disease and type-2 diabetes mellitus
Hatakawa, Y., Takeuchi, Y., Lee, S. H., & Oe, T. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107916 · Cited by 7
Flow Cytometric Evaluation of Crude Synaptosome Preparation as a Way to Study Synaptic Alteration in Neurodegenerative Diseases
Postupna, N. O., Latimer, C. S., Keene, C. D., Montine, K. S., Montine, T. J., & Darvas, M. (2018) · Neuromethods · doi:10.1007/978-1-4939-8739-9_17 · Cited by 7
A Robust and Scalable High-Throughput Compatible Assay for Screening Amyloid-β-Binding Compounds
McClure, R., Redha, R., Vinson, P. N., & Pham, W. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190316 · Cited by 7
Synthesis and evolution of neuroprotective effects of oxymatrine derivatives as anti‐Alzheimer’s disease agents
Dong, P., Li, Z., Teng, C., Yin, X., Cao, X., & Han, H. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13862 · Cited by 8
Recombinant Integrin β1 Signal Peptide Blocks Gliosis Induced by Aβ Oligomers
Ortiz-Sanz, C., Llavero, F., Zuazo-Ibarra, J., Balantzategi, U., Quintela‐López, T., Wyssenbach, A., Capetillo‐Zarate, E., Matute, C., Alberdi, E. M., & Zugaza, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105747 · Cited by 7
Different Extracellular β-Amyloid (1-42) Aggregates Differentially Impair Neural Cell Adhesion and Neurite Outgrowth through Differential Induction of Scaffold Palladin
Zhang, T., Song, C., Li, H., Zheng, Y., & Zhang, Y. (2022) · Biomolecules · doi:10.3390/biom12121808 · Cited by 7
Regulatory role of melatonin in Notch1 signaling pathway in cerebral cortex of Aβ1−42-induced Alzheimer’s disease rat model
Wang, P., Zhang, S., Hu, C., Ren, L., & Bi, J. (2023) · Molecular Biology Reports · doi:10.1007/s11033-022-08213-3 · Cited by 7
Neuroprotective Propensity of Curcumin: Evidence in Animal Models, Mechanisms, and Its Potential Therapeutic Value
Pradeep, H., Yenisetti, S. C., Rajini, P. S., & Muralidhara, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815461-8.00016-5 · Cited by 8
Acetyl-11-keto-β-boswellic acid derivatives effects on 5-lipoxygenase: In silico viewpoint
Bolbolian, S., Bozorgmehr, M. R., & Morsali, A. (2019) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2019.107464 · Cited by 7
Amyloid-β Interactions with Lipid Rafts in Biomimetic Systems: A Review of Laboratory Methods
Staneva, G., WATANABE, C., Puff, N., Yordanova, V., Seigneuret, M., & Angelova, M. I. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0814-2_4 · Cited by 8
Impact of Amidation on Aβ 25–35 Aggregation
Etaka, J. C. E., Lü, Y., Kang, W., Salsbury, F. R., & Derreumaux, P. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c07692 · Cited by 6
Direct and selective nanosensor for amyloid-β oligomers in serum for Alzheimer's disease diagnosis
Song, Q., Zhang, H., Lan, Y., Kong, J., Wong, M. S., & Li, H. (2025) · RSC Advances · doi:10.1039/d5ra01020a · Cited by 6
Rose Bengal inhibits β-amyloid oligomers-induced tau hyperphosphorylation via acting on Akt and CDK5 kinases
Mou, C., Xie, Y., Wei, J., Wang, Q.-Y., Le, J., Bao, Y., Zhang, P., Mao, Y., Huang, X.-H., Pan, H., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06232-3 · Cited by 7
Damage of the Phospholipid Bilayer by Aβ42 at Physiologically Relevant Peptide Concentrations
van Deventer, R., & Lyubchenko, Y. L. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00647 · Cited by 6
A novel recombinant 6Aβ15-THc-C chimeric vaccine (rCV02) mitigates Alzheimer’s disease-like pathology, cognitive decline and synaptic loss in aged 3 × Tg-AD mice
Yu, Y., Liu, S., Wang, H., Shi, D.-Y., Xu, Q., Zhou, X., Sun, Z., & Huang, P. (2016) · Scientific Reports · doi:10.1038/srep27175 · Cited by 6
RETRACTED ARTICLE: In situ structural characterization of early amyloid aggregates in Alzheimer’s disease transgenic mice and Octodon degus
Benseny‐Cases, N., Álvarez-Marimon, E., Aso, E., Carmona, M., Klementieva, O. L., Appelhans, D., Ferrer, I., & Cladera, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-62708-2 · Cited by 6
Retracted
Utilisation of the OliveNet™ Library to investigate phenolic compounds using molecular modelling studies in the context of Alzheimer’s disease
Liang, J. J., Pitsillou, E., Man, A. Y. L., Madzima, S., Bresnehan, S. M., Nakai, M. E., Hung, A., & Karagiannis, T. C. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107271 · Cited by 6
Rational Design of a Cu Chelator That Mitigates Cu‐Induced ROS Production by Amyloid Beta
Mitra, S., Talukdar, K., Prasad, P., Misra, S. K., Khan, S. I., Sharp, J. S., Jurss, J. W., & Chakraborty, S. (2021) · ChemBioChem · doi:10.1002/cbic.202100485 · Cited by 6
The Effect of Ethanol on Disassembly of Amyloid-β1-42 Pentamer Revealed by Atomic Force Microscopy and Gel Electrophoresis
Matsui, A., Bellier, J., Kanai, T., Satooka, H., Nakanishi, A., TERADA, T., Ishibe, T., Nakamura, Y., Taguchi, H., Naruse, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020889 · Cited by 6
Split aptazyme-based signal amplification for AβO analysis
Duan, C., Yao, Y., Cheng, W., Chen, Y., Jiao, J., & Xiang, Y. (2023) · Talanta · doi:10.1016/j.talanta.2023.125351 · Cited by 6
Improved synaptic and cognitive function in aged 3 × Tg-AD mice with reduced amyloid-β after immunotherapy with a novel recombinant 6Aβ15-TF chimeric vaccine
Yu, Y., Li, Q., Wang, H., Liu, S., Pang, X., Xu, Q., Zhou, X., & Huang, P. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.05.005 · Cited by 6
Hippocampal neurons in direct contact with astrocytes exposed to amyloid β25-35 exhibit reduced excitatory synaptic transmission
Oyabu, K., Kiyota, H., Kubota, K., Watanabe, T., Katsurabayashi, S., & Iwasaki, K. (2019) · IBRO Reports · doi:10.1016/j.ibror.2019.07.1719 · Cited by 6
The Importance of Understanding Amylin Signaling Mechanisms for Therapeutic Development in the Treatment of Alzheimer’s Disease
Servizi, S., Corrigan, R. R., & Casadesús, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200318151146 · Cited by 6
Эналаприлат ингибирует цинкзависимую олигомеризацию металлсвязывающего домена изоформ бета-амилоида и защищает клетки нейробластомы человека от их токсического действия
Kozin, S. A., Polshakov, V. I., Mezentsev, Y. V., Ivanov, A. S., Жохов, С. С., Юринская, М. М., Винокуров, М. Г., Makarov, A. А., & Mitkevich, V. A. (2018) · Molecular Biology · doi:10.1134/s0026898418040109 · Cited by 6
Excitation-Energy-Dependent Molecular Beacon Detects Early Stage Neurotoxic Aβ Aggregates in the Presence of Cortical Neurons
Gulácsy, C. E., Meade, R. M., Catici, D. A. M., Soeller, C., Pantoş, G. D., Jones, D. D., Alibhai, D., Jepson, M. A., Valev, V. K., Mason, J. M., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00322 · Cited by 6
Genome-wide association study identifies CBFA2T3 affecting the rate of CSF Aβ42 decline in non-demented elders
Dou, K., Initiative, A. D. N., Zhang, C. M., Tan, C., Xu, W., Li, J., Cao, X., Tan, L., & Yu, J. (2019) · Aging · doi:10.18632/aging.102125 · Cited by 6
Vaccination strategies
Wısnıewskı, T., & Goñi, F. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63945-5.00023-4 · Cited by 6
Reversing memory/cognitive impairment with medicinal plants targeting inflammation and its crosstalk with other pathologies
Tyler, S. E. B., & Tyler, L. D. K. (2023) · Brain Disorders · doi:10.1016/j.dscb.2023.100094 · Cited by 6
Liposomal Drug Delivery for Neurological Disorders: Advances and Challenges
Javed, A., Mandal, P., Khan, I., Singh, A. P., Akhtar, J., Maheshwari, S., & Prajapati, B. G. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249319942240903134353 · Cited by 6
Beta-Amyloid and Its Asp7 Isoform: Morphological and Aggregation Properties and Effects of Intracerebroventricular Administration
Ushakova, V. M., Zorkina, Y., Abramova, O. V., Kuanaeva, R. M., Barykin, E. P., Vaneev, A. N., Timoshenko, R. V., Gorelkin, P. V., Erofeev, A., Zubkov, E. A., et al. (2024) · Brain Sciences · doi:10.3390/brainsci14101042 · Cited by 5
An overview in interactions and biosensors of multiple biomarkers of Alzheimer’s disease
Chen, X., Wei, Y., Wang, X., Liu, X., & Wang, X. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.161121 · Cited by 5
Blockage of CCL3 with neutralizing antibody reduces neuroinflammation and reverses Alzheimer disease phenotypes
Wei, C., Liu, J., Wu, B., Shen, T., Fan, J. J., Lin, Y., Li, L., Guo, Y., Shang, Y., Zhou, B., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.034 · Cited by 9
Examination of Longitudinal Alterations in Alzheimer’s Disease-Related Neurogenesis in an APP/PS1 Transgenic Mouse Model, and the Effects of P33, a Putative Neuroprotective Agent Thereon
Szögi, T., Borbély, E., Schuster, I., Bozsó, Z., Sántha, M., Tóth, M. E., Penke, B., & Fülöp, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810364 · Cited by 6
Disassembly of Amyloid Fibril with Infrared Free Electron Laser
Kawasaki, T., Tsukiyama∥, K., & Nguyen, P. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043686 · Cited by 5
RETRACTED: Injection of exogenous amyloid-β oligomers aggravated cognitive deficits, and activated necroptosis, in APP23 transgenic mice
Yu, H., Morihara, R., Ota-Elliott, R. S., Bian, Z., Bian, Y., Hu, X., Sun, H., Fukui, Y., Abe, K., Ishiura, H., et al. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148565 · Cited by 5
Retracted
Interaction between Multimeric Sulfated Saccharides and Alzheimer Amyloid β (1-42)
Fukuda, T., Matsumoto, E., & Miura, Y. (2015) · Chemistry Letters · doi:10.1246/cl.150633 · Cited by 5
Involvement of Free Radicals in the Development and Progression of Alzheimer’s Disease
Rosales‐Hernández, M. C., Rodríguez, M. H., Wejebe, J. E. M., & Correa‐Basurto, J. (2016) · InTech eBooks · doi:10.5772/64708 · Cited by 6
The Pathogenesis Mechanism, Structure Properties, Potential Drugs and Therapeutic Nanoparticles against the Small Oligomers of Amyloid-β
Wang, K., Na, L., & Duan, M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200916123000 · Cited by 5
Quantum dots-based “chemical tongue” for the discrimination of short-length Aβ peptides
Głowacz, K., Drozd, M., Tokarska, W., Wezynfeld, N. E., & Ciosek, P. (2024) · Microchimica Acta · doi:10.1007/s00604-023-06115-0 · Cited by 5
Research application of immunomodulatory nanomaterials in Alzheimer's disease vaccine development
Guo, J., Zhang, T., Li, Y., Chen, P., Li, M., Yan, Q., & Shao, B. (2025) · Nano Biomedicine and Engineering · doi:10.1016/j.nbe.2025.100007 · Cited by 4
Amyloid-β Oligomer-Induced Electrophysiological Mechanisms and Electrical Impedance Changes in Neurons
Sun, S., Ma, Q., Sheng, Q., Huang, S., Wu, C., Liu, J., & Xu, J. (2024) · Sensors · doi:10.3390/s24041211 · Cited by 4
Unraveling APOE4's Role in Alzheimer's Disease: Pathologies and Therapeutic Strategies
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037326839241014054430 · Cited by 5
An O-glycopeptide participates in the formation of distinct Aβ42 fibril structures and attenuates Aβ42 neurotoxicity
Wei, Q., Liu, D., Xia, W., Wang, F., Huang, L., Zhang, J., Wang, X., Xu, Z., He, C., Li, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60978-w · Cited by 4
Glutathione and TRPM2 Inhibition Reduce Amyloid‐Beta and Lipopolysaccharide‐Induced Apoptosis, Inflammation, and Oxidative Stress in Microglial Cells
Akpınar, O., & Nazıroğlu, M. (2025) · Cell Biology International · doi:10.1002/cbin.70109 · Cited by 4
Protective Effect of Hydroxysafflor Yellow A against Chronic Mild Stress-induced Memory Impairments by Suppressing Tau Phosphorylation in Mice
Wang, Y., Wang, Q., Chen, J., Yao, L., Tang, N., Jiang, Z., & Luo, Y. (2021) · Current Medical Science · doi:10.1007/s11596-021-2369-3 · Cited by 4
Molecular dynamics study of water channels in natural and synthetic amyloid-β fibrils
Natesh, S. R., Hummels, A. R., Sachleben, J. R., Sosnick, T. R., Freed, K. F., Douglas, J. F., Meredith, S. C., & Haddadian, E. J. (2021) · The Journal of Chemical Physics · doi:10.1063/5.0049250 · Cited by 4
Narrative Review: Edible Plants as a Source of Valuable Flavonoids and Their Role as Neuroprotector Agents
Gutiérrez, R. M. P., & Gómez, J. T. (2022) · Current Nutrition & Food Science · doi:10.2174/1573401318666221005124312 · Cited by 4
Characterization of Olive Oil Phenolic Extracts and Their Effects on the Aggregation of the Alzheimer’s Amyloid-β Peptide and Tau
Alaziqi, B. H., Beckitt, L., Townsend, D. J., Morgan, J., Price, R., Maerivoet, A., Madine, J., Rochester, D. L., Akien, G. R., & Middleton, D. A. (2024) · ACS Omega · doi:10.1021/acsomega.4c01281 · Cited by 4
Pathomechanismen und klinische Aspekte der frontotemporalen Lobärdegeneration
Bürger, K., Arzberger, T., Stephan, J., Levin, J., & Edbauer, D. (2016) · Der Nervenarzt · doi:10.1007/s00115-016-0259-x · Cited by 4
Contribution of Diabetes and Metabolic Syndrome in the Pathogenesis of Alzheimer’s Disease
Farooqui, A. A., & Farooqui, T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811959-4.00019-5 · Cited by 4
Design, Synthesis, and Validation of a Novel [11C]Promethazine PET Probe for Imaging Abeta Using Autoradiography
Whitmore, C. A., Boules, M. I., Behof, W. J., Haynes, J. R., Koktysh, D. S., Rosenberg, A. J., Tantawy, M. N., & Pham, W. N. (2021) · Molecules · doi:10.3390/molecules26082182 · Cited by 4
Fluid Biomarkers in Clinical Trials for Alzheimer’s Disease: Current and Future Application
Yang, J., Jia, L., Li, Y., Qiu, Q., Quan, M., & Jia, J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201068 · Cited by 4
Modulating Early Stage Amyloid Aggregates by Dipeptide-Linked Perylenebisimides: Structure–Activity Relationship, Inhibition of Fibril Formation in Human CSF and Aβ1–40
Chowdhury, S. R., Balaji, S., Mondal, S., Meher, N., Trivedi, V., & Iyer, P. K. (2018) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00137 · Cited by 4
Oncostatin M, a muscle-secreted myokine, recovers high-glucose-induced impairment of Akt phosphorylation by Fos induction in hippocampal neuron cells
Hyung, W. W. S., Lee, S. G., Kim, K. T., & Kim, H. S. (2019) · Neuroreport · doi:10.1097/wnr.0000000000001271 · Cited by 4
Passive Immunization With a Novel Monoclonal Anti-PrP Antibody TW1 in an Alzheimer’s Mouse Model With Tau Pathology
Boutajangout, A., Zhang, W., Kim, J., Abdali, W., Prelli, F., & Wısnıewskı, T. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.640677 · Cited by 4
Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP/Aβ mouse model by reducing cognitive impairment, cerebral Aβ-amyloidosis, synaptic remodeling and microgliosis later in life
Latina, V., Introna, M. D., Malerba, F., Florio, R., Balzamino, B. O., Natale, G. D., Sciacca, M. F. M., Pappalardo, G., Micera, A., Pignataro, A., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02022-y · Cited by 3

Authors: Viola, K. L., & Klein, W. L.
Affiliations: Northwestern University (US)
Corresponding author: Klein, William L.
ORCID: Viola, Kirsten L.
Klein, William L.
Venue: Acta Neuropathologica
Publisher: Springer Science and Business Media LLC
Published: 2015-01-22
Volume: 129
Issue: 2
Pages: 183-206
ISSN: 0001-6322 (ISSN-L)
1432-0533
DOI: 10.1007/s00401-015-1386-3
PMC: PMC4390393
OpenAlex: W2055775253
Cited by: 628
References: 198
Citations by year: 2026: 42 · 2025: 45 · 2024: 55 · 2023: 51 · 2022: 75 · 2021: 69 · 2020: 66 · 2019: 58 · 2018: 60 · 2017: 53 · 2016: 42 · 2015: 10
FWCI: 6.76
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Acta Neuropathologica (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Institute on Aging (AG045637, AG029460, R01AG022547, AG022547, R01AG029460, R21AG045637)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: amyloid-beta oligomers, Alzheimer's disease pathogenesis, protein aggregation, neurotoxicity, synaptic dysfunction, glutamate receptors, calcium overload, tau hyperphosphorylation, insulin resistance, oxidative stress, synaptic loss, cerebrospinal fluid biomarkers, diabetes comorbidity, hypercholesterolemia, Alzheimer's disease therapeutics
MeSH terms: Alzheimer Disease, Animals, Humans, Neurons, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks